Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2025)
Historic Research & Development for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $14.0 million.
- Orchestra BioMed Holdings' Research & Development rose 2097.46% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 2971.69%. This contributed to the annual value of $42.8 million for FY2024, which is 2655.67% up from last year.
- As of Q3 2025, Orchestra BioMed Holdings' Research & Development stood at $14.0 million, which was up 2097.46% from $13.9 million recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Research & Development registered a high of $14.0 million during Q3 2025, and its lowest value of $3.5 million during Q1 2022.
- For the 4-year period, Orchestra BioMed Holdings' Research & Development averaged around $9.3 million, with its median value being $8.6 million (2023).
- Per our database at Business Quant, Orchestra BioMed Holdings' Research & Development surged by 13759.36% in 2023 and then surged by 1039.5% in 2024.
- Orchestra BioMed Holdings' Research & Development (Quarter) stood at $7.5 million in 2022, then increased by 12.83% to $8.5 million in 2023, then grew by 28.9% to $11.0 million in 2024, then increased by 27.86% to $14.0 million in 2025.
- Its Research & Development stands at $14.0 million for Q3 2025, versus $13.9 million for Q2 2025 and $13.5 million for Q1 2025.